

03-29-01

A/Box/seq

03/82/01
J-962 US
PTO

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
31508Total Pages in this Submission
51TO THE ASSISTANT COMMISSIONER FOR PATENTSBox Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

CANCER CELL-SPECIFIC HLA-F ANTIGEN AND A DIAGNOSTIC METHOD OF CANCER BY USING THEREOF

and invented by:

KOHJI EGAWA

US PTO
09/819371
JC918
03/28/01

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____
Which is a: _____

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____
Which is a: _____

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. Filing fee as calculated and transmitted as described below

2. Specification having 30 pages and including the following:

- a. Descriptive Title of the Invention
- b. Cross References to Related Applications (*if applicable*)
- c. Statement Regarding Federally-sponsored Research/Development (*if applicable*)
- d. Reference to Microfiche Appendix (*if applicable*)
- e. Background of the Invention
- f. Brief Summary of the Invention
- g. Brief Description of the Drawings (*if drawings filed*)
- h. Detailed Description
- i. Claim(s) as Classified Below
- j. Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
31508

Total Pages in this Submission
51

Application Elements (Continued)

3. Drawing(s) (*when necessary as prescribed by 35 USC 113*)
a. Formal b. Informal Number of Sheets _____
4. Oath or Declaration
 - a. Newly executed (*original or copy*) Unexecuted
 - b. Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
 - c. With Power of Attorney Without Power of Attorney
 - d. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. Incorporation By Reference (*usable if Box 4b is checked*)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. Computer Program in Microfiche
7. Genetic Sequence Submission (*if applicable, all must be included*)
 - a. Paper Copy
 - b. Computer Readable Copy
 - c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (*cover sheet & documents*)
9. 37 CFR 3.73(b) Statement (*when there is an assignee*)
10. English Translation Document (*if applicable*)
11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations
12. Preliminary Amendment
13. Acknowledgment postcard
14. Certificate of Mailing
 First Class Express Mail (*Specify Label No.:* EL759816504US)

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))


Docket No.

31508

Total Pages in this Submission

51

Accompanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) (*if foreign priority is claimed*)
16. Small Entity Statement(s) - Specify Number of Statements Submitted: _____
17. Additional Enclosures (*please identify below*):


Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

18. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

Total Pages in this Submission
51

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	25	- 20 =	5	x \$9.00	\$45.00
Indep. Claims	5	- 3 =	2	x \$40.00	\$80.00
Multiple Dependent Claims (check if applicable)	<input type="checkbox"/>				\$0.00
				BASIC FEE	\$355.00
OTHER FEE (specify purpose)					\$0.00
				TOTAL FILING FEE	\$480.00

Dated: 28 March 2001

Tracey Smith
Signature

Tracey S. Truitt, Reg. No. 43,205



23589

PATENT TRADEMARK OFFICE

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, KOHJI

Serial No. :

Filed:

CANCER CELL-SPECIFIC HLA-F
ANTIGEN AND A DIAGNOSTIC
METHOD OF CANCER BY USING
THEREOF

Docket No. 31508

Group Art Unit No.

Examiner:

JC918 U.S. PTO
09/819371
03/28/01

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

Transmitted herewith are two CD-Rs ("compact disks-write once") labeled and hereafter referred to as Copy 1 and Copy 2.


Copy 1 and Copy 2 each contain an identical copy of a sequence listing appendix associated with and incorporated by reference into the above-identified non-provisional utility application. The machine format of each CD-R is IBM-PC; and the operating system compatibility is Windows 95.

Copy 1 and Copy 2 each contain identical copies of the following ASCII files:

Filename	Size (Bytes)	Date of Creation
30518S~1.TXT	11 kb	3/28/2001

Respectfully submitted,

By


Tracey S. Truitt Reg. No. 43,205
2405 Grand Boulevard, Suite 400
Kansas City MO 64108
(816) 474-9050

ATTORNEY FOR APPLICANT(S)

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): EGAWA, KOHJI

Docket No.
31508

Serial No.	Filing Date	Examiner	Group Art Unit

Invention: CANCER CELL-SPECIFIC HLA-F ANTIGEN AND A DIAGNOSTIC METHOD OF CANCER BY USING THEREOF

09/18 U.S. PRO
09/08/01
03/28/01

I hereby certify that this Express Mail Certification; Patent Transmittal Letter (Small Entity); Application for U.S. Letters Patent including specification, claims and abstract page (30 pgs); Sequence Listing (6 pages); \$480.00 Filing Fee; Preliminary Amendment; Rule 1.821(f) Statement; Transmittal Letter; 2 copies of CD-Rs; Combined Declaration and Power of Attorney (signed); Assignment including transmittal sheet (3 pgs) with \$40.00 recordation fee; are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on March 28, 2001.

Penelope Kre

(Typed or Printed Name of person Mailing Correspondence)


(Signature of Person Mailing Correspondence)

EL759816504US

("Express Mail" Mailer Label Number)

SCANNED. # 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

EGAWA, KOHJI

Serial No. :

Group Art Unit No.

Filed:

CANCER CELL-SPECIFIC HLA-F
ANTIGEN AND A DIAGNOSTIC
METHOD OF CANCER BY USING
THEREOF

Examiner:

Box SEQ
Assistant Commissioner of Patents
Washington, D.C. 20231


Sir:

STATEMENT

Rule 1.821(f) requires a Statement to the effect that the contents of the Sequence Listing and the Computer Readable Form are the same. Such is the case for the Sequence Listing and the Computer Readable Form that accompany this Statement.

Respectfully submitted,

By


Tracey S. Truitt, Reg. No. 43,205
2405 Grand Boulevard, Suite 400
Kansas City, Missouri 64108
816/474-9050

ATTORNEYS FOR APPLICANT(S)

(Docket No. 31508)

100230-19371-032801